Definium Therapeutics, Inc.
DFTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.1B
$38.09
▲ +0.24%
P/E
-11.10
Mkt Cap
$5.1B
52-Wk Range
$12.88–$49.20
52-Week Range
$12.88 - $49.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 305.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel molecular mechanisms targeting brain health disorders
- Advanced clinical-stage pipeline with Phase 3 programs
- Differentiated R-enantiomer approach for autism treatment
- Focus on large market opportunities with significant unmet medical needs
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
MM120 Phase 3 trial progression for GAD and ADHD indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+65.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DFTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$1.44 vs -$0.54 consensus (-166.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-166.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Aug 12, 2026
vs Industry
How DFTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related